Similar Search Results

Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation

Ruof, Jörg; Schwartz, Friedrich; Schulenburg, J.-Matthias - In: The European Journal of Health Economics 15 (2014) 6, pp. 577-589

Considerable variance was observed in the levels of additional benefit reported by pharmaceutical manufacturers, IQWiG and G-BA. The areas of disagreement included ACT selection, definition of subgroups and patient-relevant endpoints, and classification and balancing of adverse events. </AbstractSection>...

Persistent link: https://www.econbiz.de/10010993901

Patient relevant endpoints in oncology : current issues in the context of early benefit assessment in Germany

Dabisch, Inna; Dethling, Jürgen; Dintsios, … - In: Health economics review 4 (2014) 2, pp. 1-8

The German AMNOG healthcare reform includes a mandatory early-benefit-assessment (EBA) at launch. As per German social …

Persistent link: https://www.econbiz.de/10010528451

AMNOG auf dem ökonomischen Prüfstand : Funktionsweise, Ergebnisse und Reformbedarf der Preisregulierung für neue Arzneimittel in Deutschland

Cassel, Dieter; Ulrich, Volker - 2015 - 1. Auflage

even launched in Germany increased by 30%.The AMNOG in its current form turns out to be a hurdle for both availability and …Seit 2011 markiert das „Arzneimittelmarktneuordnungsgesetz“ (AMNOG) eine Wende bei der Erstattung von neuen … erstattet. Nun ist dies auf maximal ein Jahr begrenzt.Parallel dazu greift die AMNOG-Preisregulierung: Dem Prinzip „Money for …